Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

The Anthem and Comcast-backed remote healthcare provider doubled its valuation for the second time in 10 months, in a series E round valuing it at $1.5bn.

HealthQuest Capital supplied $75m for the medical test provider, which counts The Chernin Group as an investor, at a flat $1.3bn valuation.

UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.

Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.

Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.

Leigh Brody and Dominik Leisi have joined Albion Capital to work on the life science investment team for UCL Technology Fund.

Unseen Capital is targeting a $100m close for a fund that will invest in healthcare technology developers run by underrepresented founders.

The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.